Summer 2026

Business Undergraduate Summer Internship

Multiple Teams

Posted on 9/12/2025

Deadline 10/22/25
Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

No salary listed

No H1B Sponsorship

Boston, MA, USA

Hybrid

Interns are expected to work from the office 4 days a week with flexibility to work remotely 1 day a week.

Category
Business & Strategy (3)
, ,
Required Skills
Financial analysis
Requirements
  • Undergraduate student working towards a bachelor’s degree; we accept current sophomore and juniors, no seniors
  • Any major(s) and no previous finance experience is required
  • Participation in on-campus activities, leadership roles, and volunteer opportunities
  • Effective communication skills, both written and verbal
  • Organized, detail-oriented, and ability to manage multiple, simultaneous tasks
  • Entrepreneurial, self-starter who is resourceful and has a curiosity to learn
  • Strong work ethic, adaptability, and interpersonal skills with the skill to collaborate in a team
Responsibilities
  • Work within a specific team in the client and infrastructure platforms
  • Support the team with day-to-day responsibilities
  • Complete ad-hoc projects with various other teams
  • Present day-to-day responsibilities, summer projects, and lessons learned to peers, mentors, and senior leaders
  • Analyze potential opportunities for new business within a geographic region or channel
  • Assist with financial analysis and modeling, budgeting, expense management
  • Support the team in evaluating potential investment opportunities
  • Collaborate with various teams to drive strategic initiatives
  • Support ongoing initiatives and may be placed in one of several teams depending on business needs
Desired Qualifications
  • Participation in on-campus activities, leadership roles, and volunteer opportunities
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$60.2B

Headquarters

Boston, Massachusetts

Founded

1933

Simplify Jobs

Simplify's Take

What believers are saying

  • Hartford Funds adds advisor distribution and deepens U.S. wealth reach.
  • Liquid alternatives expansion can capture demand for market-neutral strategies in volatile markets.
  • Sustainable investing and climate-aware portfolios can win mandates from institutions.

What critics are saying

  • Hartford integration faces regulatory delays and execution risk until Q1 2027.
  • Fee compression threatens revenue as institutions pressure pricing on large mandates.
  • Sustained underperformance would trigger redemptions, talent departures, and severe brand damage.

What makes Wellington Management unique

  • Independent private partnership since 1928, with nearly 50 investment teams.
  • Combines research, trading, data science, and client service across asset classes.
  • Manages $1.3 trillion through globally integrated, boutique-style investment approaches.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Wellington Management who can refer or advise you

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.

INACTIVE